The pro-allergic function of Irf1−/− Th9 cells was ameliorated by treatment with IL-9-neutralizing antibodies as determined by decrease in eosinophilia, in the numbers of mucus-producing cells and in inflammation (Fig. 5f–h, Supplementary Fig. 6b,c). This evidence concerns the gene IL9 and Increased total eosinophil count.